Trends: NAS Launches and NME Approvals Rise and Fall - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Trends: NAS Launches and NME Approvals Rise and Fall

Pharmaceutical Technology
Volume 32, Issue 10, pp. 28

Companies launched 25 new active substances (NAS) in 2007, a decline of 19% from the previous year, according to an August report from Parexel International. The consulting firm's US Drug Approval Trends and Yearbook 2008–2009 also reveals that only 16 new molecular entities (NMEs) were approved in the US during 2007. Yet the number of US-marketing applications filed for NMEs rose to 28 in 2007, a 33% increase from 2006.

"NME and NAS approvals are key measures of new-drug productivity in the biopharmaceutical industry, and these measures tend to improve based on the volume of new-drug submissions," said Mark Mathieu, director of publications at Parexel, in a press release. He called the recent increase in the number of NME submissions an encouraging sign.

In the press release, Mathieu also said Parexel's analysis shows that "record percentages of drug-marketing applications that the US Food and Drug Administration has designated as priority submissions are going straight to approval in the first review cycle."

Among the NMEs that FDA approved in 2007 were Novartis's (Basel) hypertension drug "Tekturna," GlaxoSmithKline's (London) breast-cancer treatment "Tykerb," and Merck's (Whitehouse Station, NJ) HIV treatment "Isentress."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here